Comerica Bank Buys 140,767 Shares of Evolus, Inc. $EOLS

Comerica Bank boosted its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 497.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,068 shares of the company's stock after purchasing an additional 140,767 shares during the period. Comerica Bank owned 0.26% of Evolus worth $2,034,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. AlphaQuest LLC acquired a new position in Evolus in the 1st quarter worth about $39,000. IFP Advisors Inc increased its stake in shares of Evolus by 99.0% in the first quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock valued at $113,000 after buying an additional 4,691 shares during the period. Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the fourth quarter valued at about $115,000. Man Group plc acquired a new stake in shares of Evolus in the fourth quarter valued at about $121,000. Finally, Freestone Grove Partners LP acquired a new stake in shares of Evolus in the fourth quarter valued at about $140,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Insider Buying and Selling

In related news, Director Brady Stewart bought 30,000 shares of the company's stock in a transaction dated Friday, August 15th. The shares were bought at an average price of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the acquisition, the director directly owned 88,629 shares of the company's stock, valued at $604,449.78. This trade represents a 51.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Moatazedi sold 111,323 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $10.05, for a total value of $1,118,796.15. Following the completion of the transaction, the insider owned 381,509 shares in the company, valued at $3,834,165.45. This represents a 22.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 133,627 shares of company stock worth $1,325,764 over the last three months. Company insiders own 6.10% of the company's stock.

Evolus Trading Up 2.0%

Shares of Evolus stock traded up $0.15 on Friday, hitting $7.66. 534,857 shares of the company's stock traded hands, compared to its average volume of 1,045,975. The company has a market capitalization of $495.45 million, a price-to-earnings ratio of -7.82 and a beta of 1.07. Evolus, Inc. has a one year low of $5.71 and a one year high of $17.82. The company has a fifty day moving average of $8.26 and a two-hundred day moving average of $10.13. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86.

Analyst Upgrades and Downgrades

EOLS has been the subject of several recent research reports. Wall Street Zen cut Evolus from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. BTIG Research decreased their price target on Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Needham & Company LLC reissued a "hold" rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, August 6th. Finally, HC Wainwright decreased their price target on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.